Gilead Sciences shows positive results for remdesivir as COVID-19 drug
Category: #health  By Mateen Dalal  Date: 2020-05-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Gilead Sciences shows positive results for remdesivir as COVID-19 drug

Gilead Sciences, the maker of remdesivir, has recently revealed positive results from trials for the drug. The trials were conducted to evaluate the potential of the medication as a treatment for the novel coronavirus.

The trials examined the response of patients to either 5-day or 10-day treatments of remdesivir. According to Gilead, the patients undergoing the 5-day treatment showed similar improvement as those treated for twice the timeframe.

Merdad Parsey, Gilead Sciences’ chief medical officer has reportedly stated that the trial shows the potential of certain patients to be treated under the 5-day remdesivir regimen, which could considerably increase the number of patients that could be treated with the present remdesivir supply. This could prove extremely beneficial in the current pandemic setting, enabling healthcare facilities and hospitals to provide efficient treatment to patients in urgent need.

The drug is also being tested locally. For instance, St. Joseph Hospital revealed its plans to conduct some remdesivir trials earlier in the month, which marks a significant feat for the small rural facility. The hospital is conducting two clinical trials, one for moderate symptoms and one to treat more severe symptoms.

Chief executive of St. Joseph Health, Dr. Roberta Luskin-Hawk, stated that one of the patients to receive the treatment was a local patient hospitalized at the St. Joseph Hospital, exhibiting severe COVID-19 symptoms, including dropping oxygen, making them an ideal trial candidate. Dr. Luskin-Hawk also expressed her belief that the drug shows promise as a potential COVID-19 treatment. She also recounted her anticipation to gain access to the drug, in order to leverage its ability to reduce viral loads in patients, especially those suffering from the coronavirus.

The hospital has not offered further information regarding the local trials.

There are no medications currently approved for the treatment of COVID-19, a respiratory disorder that has claimed the lives of over 227,000 people across the globe.

Source Credit: https://www.times-standard.com/2020/04/29/covid-19-drug-shows-promise-in-two-clinical-trials/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

NSW calls for project ideas for its 1st renewable zone in Central West
NSW calls for project ideas for its 1st renewable zone in Central West
By Mateen Dalal

Public intervention in any form of producing unique ideas and solutions to support the government initiatives, has always been acclaimed as a commendable effort. This eventually has urged various state and central governments to lay their focus on as...

Teva presents AJOVY’s new data on migraine impact in European adults
Teva presents AJOVY’s new data on migraine impact in European adults
By Mateen Dalal

The analysis examines impact of migraine in areas of Spain, France, and the United Kingdom. Migraine has been one of the prominent neurological conditions that is mostly prevalent in adults and can cause multiple symptoms such as throbbing headac...

Australia researchers introduce an internet speed record of 44.2 Tbps
Australia researchers introduce an internet speed record of 44.2 Tbps
By Mateen Dalal

In these crucial times, when high speed internet has become a necessity for all those company employees working from home or the students studying through online courses, Australian researchers have achieved a breakthrough in the bringing forth the f...